ArticlePsoriasis (Auckland, N.Z.)2021

Efficacy of Brodalumab and Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis Who are Inadequate Responders to Ustekinumab: A Matching Adjusted Indirect Comparison.

Philip Hampton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.